Table 2.
Summary of AEs reported in ≥ 2 participants receiving doses of 7–70 mg RO7497987.
| AE preferred term | SAD1 0.7 mg (n=6) |
SAD2 2.1 mg (n=6) |
SAD3 7.0 mg (n=6) |
SAD4 21 mg (n=6) |
SAD5 70 mg (n=7) |
MAD1 7.0 mg (n=6) |
MAD2 21 mg (n=6) |
Total (N = 43) |
Total related (N = 43) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gr1 | Gr2 | Gr1 | Gr2 | Gr1 | Gr2 | Gr1 | Gr2 | Gr1 | Gr2 | Gr1 | Gr2 | Gr1 | Gr2 | All Grade | All Grade | |
| Headache | 1 (17%) | 3 (50%) | 4 (9%) | 3 (7%) |
||||||||||||
| Myalgia | 1 (17%) | 2 (33%) | 1 (17%) | 4 (9%) | 4 (9%) | |||||||||||
| Covid-19 | – | – | – | – | – | – | 1 (17%) | – | 1 (14%) | – | – | – | – | – | 2 (5%) |
0 |
| Lymphadenopathy | – | – | – | – | – | – | – | – | – | – | 1 (17%) | – | 2 (33%) | – | 3 (7%) |
3 (7%) |
| Upper respiratory tract infection | – | – | – | – | – | – | 2 (33%) | – | – | – | – | – | 1 (17%) | – | 3 (7%) |
0 |